Nrf1 can be processed and activated in a proteasome-independent manner

Current Biology

Volumn 26, Issue 18, 2016, Pages R834-R835

  Vangala, Janakiram R ^a   Sotzny, Franziska ^b   Krüger, Elke ^b   Deshaies, Raymond J ^c   Radhakrishnan, Senthil K ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c California Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NRF1 PROTEIN, HUMAN; NRF1 PROTEIN, MOUSE; NUCLEAR RESPIRATORY FACTOR 1; PROTEASOME; PROTEASOME INHIBITOR;

ANIMAL; CELL LINE; DRUG EFFECTS; ENDOPLASMIC RETICULUM; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MOUSE; NIH 3T3 CELL LINE;

ANIMALS; CELL LINE; ENDOPLASMIC RETICULUM; HEK293 CELLS; HUMANS; MICE; NIH 3T3 CELLS; NUCLEAR RESPIRATORY FACTOR 1; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS;

EID: 84992126914     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cub.2016.08.008     Document Type: Letter

References (10)

1. 1 Radhakrishnan, S.K., Lee, C.S., Young, P., Beskow, A., Chan, J.Y., Deshaies, R.J., Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol. Cell 38 (2010), 17–28.
2. 2 Steffen, J., Seeger, M., Koch, A., Kruger, E., Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. Mol. Cell 40 (2010), 147–158.
3. 3 Radhakrishnan, S.K., den Besten, W., Deshaies, R.J., p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition. eLife, 3, 2014, e01856.
4. 4 Sha, Z., Goldberg, A.L., Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97. Curr. Biol. 24 (2014), 1573–1583.
5. 5 Wang, W., Chan, J.Y., Nrf1 is targeted to the endoplasmic reticulum membrane by an N-terminal transmembrane domain. Inhibition of nuclear translocation and transacting function. J. Biol. Chem. 281 (2006), 19676–19687.
6. 6 Deshaies, R.J., Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Biol., 12, 2014, 94.
7. 7 Lehrbach, N.J., Ruvkun, G., Proteasome dysfunction triggers activation of SKN-1A/Nrf1 by the aspartic protease DDI-1. eLife, 5, 2016, 10.7554/eLife.17721.
8. 8 Koizumi, S., Irie, T., Hirayama, S., Sakurai, Y., Yashiroda, H., Naguro, I., Ichijo, H., Hamazaki, J., Murata, S., The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction. eLife, 5, 2016, 10.7554/eLife.18357.
9. 9 Magnaghi, P., D'Alessio, R., Valsasina, B., Avanzi, N., Rizzi, S., Asa, D., Gasparri, F., Cozzi, L., Cucchi, U., Orrenius, C., et al. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat. Chem. Biol. 9 (2013), 548–556.
10. 10 Downey, S.L., Florea, B.I., Overkleeft, H.S., Kisselev, A.F., Use of proteasome inhibitors. Curr. Protoc. Immunol. 109 (2015), 9–18.